Cleanlink News | 4/19/2012
Martin D. Chapman, PhD, Accepts Seat on PCHS Advisory
Dr. Martin D. Chapman, PhD, has accepted a seat on the Process Cleaning for Healthy Schools (PCHS) Consortium Advisory. The Process Cleaning for Healthy Schools (PCHS) Consortium is a national non-profit organization of facility professionals dedicated to helping its members produce healthy, high performance schools while protecting jobs in budget-constrained environments.
Martin D. Chapman, PhD graduated with a BSc. (Hons) in Applied Biology in 1976 and received his PhD in Immunology in 1981 from the Royal Postgraduate Medical School, University of London, U.K. Dr. Chapman had postdoctoral fellowships at the London School of Hygiene and Tropical Medicine and at UCLA School of Medicine. He has been a Faculty member at the University of Virginia since 1985 and became a tenured Professor of Medicine in 1997.
Dr. Chapman's scientific research focused on the molecular and structural properties of dust mite, cat, dog, cockroach and fungal allergens and their role in causing allergic diseases, especially asthma. Most recently, this involved molecular cloning and expression of indoor allergens, production of hypoallergenic variants by site directed mutagenesis, and analysis of allergen specific immune responses. Other research interests include the relationship between environmental allergen exposure and allergic disease, the aerodynamic properties of indoor allergens and allergen avoidance procedures. Dr. Chapman was the first recipient of the Pharmacia Allergy Research Foundation Award in 1987 and has authored or co-authored over 200 scientific articles, book chapters, reviews and proceedings.
Dr. Chapman received numerous NIH grants and was a Co-Director of the University of Virginia Asthma and Allergic Diseases Center from 1993-2001. Dr. Chapman serves on the Editorial Boards of allergy and immunology journals and on committees of the American Academy of Allergy, Asthma and Immunology (AAAAI). He is Past Chair of the Environmental Occupational and Respiratory Disorders Interest Section of the AAAAI and of the World Health Organization/International Union of Immunological Societies Sub-Committee on Allergen Standardization. Dr. Chapman has served as an ad hoc member on study sections for National Institute of Allergy and Infectious Disease and on Scientific Advisory Boards for the Environmental Protection Agency and the Food Allergy Initiative. Dr. Chapman is also a member of the Board of Directors of the Virginia Biotechnology Organization (VABIO, 2006-08).
In 1995, Dr. Chapman founded the INDOOR Biotechnologies (IB) companies, based in Warminster, U.K. and Charlottesville, VA (www.inbio.com). Since 2001, Dr. Chapman has been President of INDOOR Biotechnologies Inc. and has retained an adjunct appointment as Clinical Professor of Medicine at the University of Virginia. INDOOR Biotechnologies specializes in environmental allergen detection systems and genetically engineered allergens. The company has several product lines, including ELISA and MARIA systems for allergen analysis; purified natural, recombinant and LoTox allergens, and rapid tests for allergen detection in the home, which are designed for use by consumers. The company has active research programs which are supported by Small Business Innovation and Research (SBIR) grants from the National Institutes of Health. IB revenues have more than doubled over the past five years and the company is well positioned for future growth.